PetMed Express (NAS: PETS) is expected to report Q2 earnings on Oct. 22. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express's revenues will drop -2.0% and EPS will wither -10.5%.
The average estimate for revenue is $57.0 million. On the bottom line, the average EPS estimate is $0.17.
Last quarter, PetMed Express tallied revenue of $69.0 million. GAAP reported sales were 6.3% lower than the prior-year quarter's $73.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.20. GAAP EPS of $0.20 for Q1 were 9.1% lower than the prior-year quarter's $0.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 32.3%, 50 basis points worse than the prior-year quarter. Operating margin was 9.0%, 130 basis points worse than the prior-year quarter. Net margin was 5.7%, 90 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $230.0 million. The average EPS estimate is $0.71.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 873 members out of 901 rating the stock outperform, and 28 members rating it underperform. Among 202 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 193 give PetMed Express a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is underperform, with an average price target of $10.80.
Can your portfolio provide you with enough income to last through retirement? You'll need more than PetMed Express. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.
Add PetMed Express to My Watchlist.
The article What to Expect from PetMed Express originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.